AzTrials
AzTrials

Newborn Cardiac SurgeryhemostasisNCT06166940

Comparison Of The Two Types Of Hemostasis Management Effectiveness : Thromboelastometry (Rotem) Guided Management And Conventional Method In Newborn Congenital Cardiac Surgery Patients

An observational study of Newborn Cardiac Surgery and Newborn Hemostasis, run by Başakşehir Çam & Sakura City Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Sixty consecutive newborn patients who underwent pediatric cardiac surgery from April 2022 to October 2023 at Basaksehir Cam and Sakura City Hospital) were included in this study. Data of eighty-six patients who received ROTEM guided transfusions after August 15, 2022 was collected. Read more about this study

Who is it for?
Ages 0 to 30 days
Conditions the study is for
Newborn Cardiac Surgery, Newborn Hemostasis
What is being tested?
ROTEM Guided Management
How many people
60 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Mar 2022to 1 Oct 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 30 days
  • All sexes
  • No healthy volunteers
  • Child

Study population: Newborn patients who underwent pediatric congenital heart surgery on cardiopulmonary bypass

Who may be able to join

  • newborn patients who underwent pediatric congenital heart surgery on cardiopulmonary bypass

Who cannot join

  • the newborn patients who did not need cardiopulmonary bypass during surgery were excluded.
  • the newborns whose records are missing were excluded

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Basaksehir Cam and Sakura City Hospital

    Istanbul

Other trials in Turkey (Türkiye)

About this study

Sixty consecutive newborn patients who underwent pediatric cardiac surgery from April 2022 to October 2023 at Basaksehir Cam and Sakura City Hospital) were included in this study. Data of eighty-six patients who received ROTEM guided transfusions after August 15, 2022 was collected. First sixteen patients were given cryoprecipitate in the middle of the Modified ultra-filtration (MUF) procedure according to previous conventional approach, and so these patients excluded. And ten patients were excluded due to the lack of information. Thirty patients, who received ROTEM guided transfusions compared to the prior thirty patients who received transfusions conventionally. There was no randomization and standardized anesthesia and surgical techniques were used.

Anesthesia induction conducted with midazolam, ketamine, fentanyl, and rocuronium bromide; and antifibrinolytic (tranexamic acid) infusion was used during operation till the closure of skin. Anesthesia and cardiopulmonary bypass(CPB) anesthesia was maintained with remifentanil, midazolam, ketamine and rocuronium, and sevoflurane -not during bypass. Size-adapted bypass circuits and membrane oxygenators (FX05 oxygenators) were used. Total priming volume for the bypass circuit was 250 - 400 ml, consisting of red blood cell (RBC), fresh frozen plasma (FFP), Isolyte-S solution, mannitol, sodium bicarbonate, tranexamic acid, prednisol, and antibiotic. Anticoagulation during CPB was managed with 350 U/kg unfractioned heparin (Novo-Heparin) and additional boluses of 50 U/kg, as needed, to maintain an activated clotting time (ACT) of at least 450s. Heparin anticoagulation was antagonized with 3,5 mg/kg protamine.

Read more

Red blood cell concentrates were transfused to maintain the haematocrit at 28 - 32% during cardiopulmonary bypass (CPB). Bypass was conducted under mild (core temperature 32°C ) and moderate (core temperature 28 °C) hypothermia. Myocardial protection was achieved with cold intermittent blood cardioplegia (20 ml/kg), which was prepared during CPB by adding buffered del nido solution (Plasma-Lyte A) in the ratio 1:4 to whole blood obtained from the arterial line. The cardioplegia solution was kept at 6°C before infusion. Blood sample for running ROTEM analysis were taken just before weaning CPB, when the core temperature of patients were 36-37 °C. MUF was performed after weaning from CPB and 5-10 minutes before protamine administration, with a target haematocrit of 35-40%. After heparin antagonization, RBC transfusions applied with a target haematocrit of 35-40 % for non-cyanotic patients, and 40-45% for cyanotic patients.

We collected data on the following subject characteristics: height (cm); weight (kg); age (days); gender; presence of cyanosis; presence of ay genetic disorder; Aristotle score (1,5-25); duration of the surgical procedure (min); CPB time (min); aortic cross clamp time (min); the lowest core temperature during CPB; total amount of blood products transfused after CPB intraoperatively (ml/kg), including red blood cell concentrates, FFP, platelet concentrates, cryoprecipitate, and fibrinogen concentrates; total amount of blood products transfused after operation up to 24 h after admission to the Pediatric Cardiac Intensive Care Unit (PCICU) (ml/kg); total amount of chest tube drainage after operation up to 24 h after PCICU admission (ml/kg); 28 day survival; extracorporeal membrane oxygenator (ECMO) application; and need for peritoneal dialysis.

In all patients, routine blood samples for hemoglobin (Hb), haematocrit (Hct), prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), platelet count; renal function tests urea and creatinine were collected preoperatively. Hb, Hct, PT, INR, aPTT, platelet count, urea and creatinine were also analyzed on the first postoperative morning.

We conducted thromboelastometry in the operating theatre (OR) using the ROTEM device. Four assays-EXTEM, INTEM, FIBTEM, and HEPTEM were tested in citrated whole blood. Because the patients were still under heparin effect when the samples were taken, we made transfusion adjustments according to EXTEM and FIBTEM test results. Since we got the EXTEM, FIBTEM A5 results as soon as heparin antagonization was complete, we transfused the blood products according to the results. We also collected those data.

The primary outcome was the proportion of perioperative transfusion (intraoperatively and in the PCICU) in the ROTEM group and in the conventional group. The secondary outcomes are postoperative chest tube drainage up to 24 hours; need for peritoneal dialysis. The other analyses have mainly a descriptive purpose.

Read the detailed description

Four main scenarios based on clinical observation and ROTEM results were possible:

  1. Insignificant bleeding-normal ROTEM; no transfusions
  2. Insignificant bleeding-abnormal ROTEM; no transfusions
  3. Significant bleeding-normal ROTEM; surgical reevaluation
  4. Significant bleeding-abnormal ROTEM; transfusion of blood products as indicated by:
  5. FIBTEM A5 <9 mm -fibrinogen concentrate or cryoprecipitate
  6. 9mm ≤ FIBTEM A5 <13mm and or EXTEM CT > 80 seconds fibrinogen concentrate or cryoprecipitate and significant bleeding still continued with EXTEM A5 < 35 mm - platelet concentrate
  7. FIBTEM A5 >13mm and EXTEM A5 < 35 mm -platelet concentrate
  8. After transfusions if the bleeding was still continuing, while surgical reevaluation was in progress, we gave fibrinogen concentrate to replace the lost fibrinogen with the ongoing bleeding. At the same time to verify the treatment effect and control heparin reversal, a second set of INTEM, HEPTEM, EXTEM and FIBTEM analyses were also performed during wound closure. ACT was tested in all patients to control for heparin reversal. If patients had both a pathological ACT and ROTEM (CTIN/ CTHEP ratio ≥ 1,25) protamine was administered first. After fibrinogen and platelet transfusions, if INTEM CT > 280 seconds and HEPTEM CT > 280 seconds with continuing bleeding FFP were given.

Blood transfusion after paediatric intensive care unit (PCICU) admission was managed without ROTEM guidance by paediatric cardiac surgeons and intensivists.

Being tested
ROTEM Guided Management

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ROTEM Guided ManagementOther

    ROTEM guided management of hemostasis after CPB

Study groups in NCT06166940
Study groupRoleWhat they receive
Conventional ManagementNot described
Receives: Other: ROTEM Guided Management

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. perioperative transfusion

    the proportion of perioperative transfusion of RBC, fibrinogen concentrate, platelet concentrate, FFP in milliliters

    Measured: after weaning from cardiopulmonary bypass up to the end 24 hours

Secondary outcomes (1)
  1. postoperative bleeding

    postoperative chest tube drainage in milliliters

    Measured: from the admission of the pediatric cardiac intensive care unit up to 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Dec 2023
  2. Study start1 Mar 2022
  3. Primary completion1 Oct 2023
  4. Study completion1 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Retrospective
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06166940
Sponsor's protocol ID
2023.11.11
Acronym
hemostasis
Status last verified
Mar 2022
First submitted
4 Dec 2023
Last updated
12 Dec 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Newborn Cardiac Surgery and Newborn Hemostasis, run by Başakşehir Çam & Sakura City Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

perioperative transfusion (time frame: after weaning from cardiopulmonary bypass up to the end 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in